For: | De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v25/i33/4933.htm |
Number | Citing Articles |
1 |
Anand V. Kulkarni, Madhumita Premkumar, Juan P. Arab, Karan Kumar, Mithun Sharma, Nageshwar D. Reddy, Nagaraja R. Padaki, Rajender K. Reddy. Early Diagnosis and Prevention of Infections in Cirrhosis. Seminars in Liver Disease 2022; 42(03): 293 doi: 10.1055/a-1869-7607
|
2 |
Shiyan Wu, Lu Li, Heng Xi, Xiaoping Wu, Yumei He, Xiaobin Sun, Liping Wu. Bibliometrics and knowledge mapping of the pathogenesis of hepatic encephalopathy in patients with liver cirrhosis. Heliyon 2024; 10(15): e34330 doi: 10.1016/j.heliyon.2024.e34330
|
3 |
Shanshan Sun, Wenyi Ye, Ruihong Zhao, Jianhua Hu, Xuan Zhang, Meifang Yang, Hong Zhao, Jifang Sheng. Proton Pump Inhibitor Therapy Does Not Affect Prognosis of Cirrhosis Patients With Acute Decompensation and Acute-on-Chronic Liver Failure: A Single-Center Prospective Study. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.763370
|
4 |
Luísa Martins Figueiredo, Maria Ana Rafael, Gonçalo Alexandrino, Joana C. Branco, Rita Carvalho, Mariana Nuno Costa, Alexandra Martins. Risk factors for the emergence of multidrug-resistant organisms in liver cirrhosis. Gastroenterología y Hepatología (English Edition) 2022; 45(3): 186 doi: 10.1016/j.gastre.2021.04.006
|
5 |
Liza Cholin, Tarek Ashour, Ali Mehdi, Jonathan J. Taliercio, Remy Daou, Susana Arrigain, Jesse D. Schold, George Thomas, Joseph Nally, Nazih L. Nakhoul, Georges N. Nakhoul. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression. BMC Nephrology 2021; 22(1) doi: 10.1186/s12882-021-02449-0
|
6 |
Amit Kumar Dutta, Abhinav Jain, Vaneet Jearth, Ramit Mahajan, Manas Kumar Panigrahi, Vishal Sharma, Mahesh Kumar Goenka, Rakesh Kochhar, Govind Makharia, Duvvur Nageshwar Reddy, Richard Kirubakaran, Vineet Ahuja, Neha Berry, Naresh Bhat, Usha Dutta, Uday Chand Ghoshal, Ajay Jain, Umesh Jalihal, V. Jayanthi, Ajay Kumar, Sandeep Nijhawan, Ujjal Poddar, G. N. Ramesh, Shivram P Singh, Showkat Zargar, Shobna Bhatia. Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship. Indian Journal of Gastroenterology 2023; 42(5): 601 doi: 10.1007/s12664-023-01428-7
|
7 |
Keiji Yokoyama, Naoaki Tsuchiya, Ryo Yamauchi, Takashi Miyayama, Yotaro Uchida, Kumiko Shibata, Hiromi Fukuda, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Shinjiro Inomata, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai. Exploratory Research on the Relationship between Human Gut Microbiota and Portal Hypertension. Internal Medicine 2020; 59(17): 2089 doi: 10.2169/internalmedicine.4628-20
|
8 |
Ummi Maimunah, Andreas Agung Kurniawan, Andrio Palayukan. Adverse Effects of Long-term Proton Pump Inhibitors in Chronic Liver Disease Patients – A Preliminary Article Review. Review of Clinical Pharmacology and Pharmacokinetics - International Edition 2024; 38(1): 87 doi: 10.61873/WWAY6273
|
9 |
Nadim Mahmud, Marina Serper, Tamar H. Taddei, David E. Kaplan. The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Gastroenterology 2022; 163(1): 257 doi: 10.1053/j.gastro.2022.03.052
|
10 |
Lukas Sturm, Chiara Gahm, Michael Schultheiss, Marlene Reincke, Jan Patrick Huber, Tobias Boettler, Robert Thimme, Dominik Bettinger. Proton pump inhibitor treatment is associated with acute-on-chronic liver failure in patients with advanced cirrhosis. Hepatology Communications 2023; 7(7) doi: 10.1097/HC9.0000000000000178
|
11 |
Raphaël Eftimie Spitz, Stefan Lucian Popa, Simona Grad, Dan Lucian Dumitrascu, Abdulrahman Ismaiel, Teodora Surdea-Blaga. The Use of Proton Pump Inhibitors in Patients with Liver Cirrhosis: Real Life Experience. Journal of Clinical Medicine 2024; 13(17): 5155 doi: 10.3390/jcm13175155
|
12 |
Wenlei Liu, Jana Jakobs, Lothar Rink. Proton-Pump Inhibitors Suppress T Cell Response by Shifting Intracellular Zinc Distribution. International Journal of Molecular Sciences 2023; 24(2): 1191 doi: 10.3390/ijms24021191
|
13 |
Moloud Balafar, Morteza Ghojazadeh, Kavous Shahsavarinia, Zahra Parsian, Saba Hamedani, Hassan Soleimanpour. Association Between Proton Pump Inhibitor Use and Spontaneous Bacterial Peritonitis or Hepatic Encephalopathy in Cirrhotic Patients: A Systematic Review and Meta-analysis. Hepatitis Monthly 2023; 23(1) doi: 10.5812/hepatmon-132642
|
14 |
Yuan Bin Liu, Ming Kai Chen. The impact of proton pump inhibitors in liver diseases and the effects on the liver. Journal of Digestive Diseases 2022; 23(4): 196 doi: 10.1111/1751-2980.13093
|
15 |
Raquel de Oliveira Coberllini JACQUES, Lais da Silva MASSIGNAN, Martina Schumacher WINKLER, Rafael Sartori BALBINOT, Silvana Sartori BALBINOT, Jonathan SOLDERA. ACUTE-ON-CHRONIC LIVER FAILURE IS INDEPENDENTLY ASSOCIATED WITH LOWER SURVIVAL IN PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS. Arquivos de Gastroenterologia 2021; 58(3): 344 doi: 10.1590/s0004-2803.202100000-58
|
16 |
|
17 |
Meng Zhang, Xin Xu, Wei Liu, Zhongwei Zhang, Qiuyu Cheng, Zhongyuan Yang, Tingting Liu, Yunhui Liu, Qin Ning, Tao Chen, Junying Qi. Proton Pump Inhibitor Therapy Increases the Risk of Spontaneous Bacterial Peritonitis in Patients with HBV-Related Acute-on-Chronic Liver Failure. Advances in Therapy 2021; 38(9): 4675 doi: 10.1007/s12325-021-01844-1
|
18 |
Luísa Martins Figueiredo, Maria Ana Rafael, Gonçalo Alexandrino, Joana C. Branco, Rita Carvalho, Mariana Nuno Costa, Alexandra Martins. Risk factors for the emergence of multidrug-resistant organisms in liver cirrhosis. Gastroenterología y Hepatología 2022; 45(3): 186 doi: 10.1016/j.gastrohep.2021.04.006
|
19 |
Hyun Jin Song, Xinyi Jiang, Linda Henry, Mindie H. Nguyen, Haesuk Park. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. European Journal of Clinical Pharmacology 2020; 76(6): 851 doi: 10.1007/s00228-020-02854-8
|
20 |
Xiaoli Wu, Daofu Zhang, Yuexiao Yu, Lianqing Lou, Xiaofei Li. Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies. Bioscience Reports 2020; 40(6) doi: 10.1042/BSR20193890
|
21 |
Hassan Ghoz, Payal Patel, Fernando Stancampiano, Sheetal Patel, Erin A. Fox, Mohammad B. Yousaf, Mohamed Omer, Michael G. Heckman, Matthew R. Spiegel, William C. Palmer. Proton-pump-inhibitor use associated with lower short-term rebleeding and mortality in patients receiving esophageal variceal band ligation: a retrospective cohort study. European Journal of Gastroenterology & Hepatology 2020; 32(12): 1571 doi: 10.1097/MEG.0000000000001905
|
22 |
Xiaoning Chen, Tao Zhou, Ting Zhou, Yueyue Li, Xin Sun, Baoquan Cheng, Ning Zhong, Xuefeng Lu, Yanjing Gao. Effects of proton pump inhibitor on gastroesophageal varices in patients with cirrhosis: A randomized controlled trial from China. Portal Hypertension & Cirrhosis 2023; 2(1): 1 doi: 10.1002/poh2.37
|
23 |
L. Majano Díaz, D. Villascusa Arenas, J. Martínez González, L. Téllez Villajos. Hipertensión portal en el paciente cirrótico, varices esofágicas, gastropatía y sangrado digestivo. Medicine - Programa de Formación Médica Continuada Acreditado 2024; 14(10): 550 doi: 10.1016/j.med.2024.05.011
|
24 |
Gasser El-Azab. Proton Pump Inhibitors in Patients with Cirrhosis: Pharmacokinetics, Benefits and Drawbacks. Current Gastroenterology Reports 2024; 26(12): 323 doi: 10.1007/s11894-024-00943-7
|
25 |
Thomas H. Tranah, Victoria T. Kronsten, Debbie L. Shawcross. Implications and Management of Cirrhosis‐Associated Immune Dysfunction Before and After Liver Transplantation. Liver Transplantation 2022; 28(4): 700 doi: 10.1002/lt.26353
|
26 |
Chia-Jung Kuo, Cheng-Yu Lin, Chun-Wei Chen, Chiu-Yi Hsu, Sen-Yung Hsieh, Cheng-Tang Chiu, Wey-Ran Lin. Risk of Enteric Infection in Patients with Gastric Acid Supressive Drugs: A Population-Based Case-Control Study. Journal of Personalized Medicine 2021; 11(11): 1063 doi: 10.3390/jpm11111063
|
27 |
Zhen Yu Wong, Jia Hong Koh, Mark Muthiah, Benjamin Koh, Elden Yen Hng Ong, Christen En Ya Ong, Kai Qi Ou, Wen Hui Lim, Darren Jun Hao Tan, Douglas Chee, Kewin Tien Ho Siah, Yujun Wong, Apichat Kaewdech, Karn Wijarnpreecha, Anand V. Kulkarni, Benjamin Nah, Daniel Q. Huang, Mazen Noureddin, Cheng Han Ng, Margaret Teng. Proton Pump Inhibitors Increases Longitudinal Risk of Mortality, Decompensation, and Infection in Cirrhosis: A Meta-Analysis. Digestive Diseases and Sciences 2024; 69(1): 289 doi: 10.1007/s10620-023-08150-6
|
28 |
Lukas Sturm, Laura Muller, Michael Schultheiss, Benedikt Binder, Jan Patrick Huber, Robert Thimme, Dominik Bettinger. Proton pump inhibitor therapy is associated with reduced survival following first-time transarterial chemoembolization in patients with hepatocellular carcinoma. European Journal of Gastroenterology & Hepatology 2021; 33(1S): e247 doi: 10.1097/MEG.0000000000002018
|
29 |
Kim Jun Kevin Teh, Hai Kiat Troy Puar, Choon How How, Teck Kiang Malcolm Tan. Deprescribing proton pump inhibitors. Singapore Medical Journal 2023; 64(8): 503 doi: 10.4103/singaporemedj.SMJ-2021-445
|
30 |
Alana Zulian Terres, Rafael Sartori Balbinot, Ana Laura Facco Muscope, Morgana Luisa Longen, Bruna Schena, Bruna Teston Cini, Gilberto Luis Rost, Juline Isabel Leichtweis Balensiefer, Louise Zanotto Eberhardt, Raul Angelo Balbinot, Silvana Sartori Balbinot, Jonathan Soldera. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. Gastroenterología y Hepatología 2022; 45(1): 25 doi: 10.1016/j.gastrohep.2021.02.007
|
31 |
Alana Zulian Terres, Rafael Sartori Balbinot, Ana Laura Facco Muscope, Morgana Luisa Longen, Bruna Schena, Bruna Teston Cini, Gilberto Luis Rost, Juline Isabel Leichtweis Balensiefer, Louise Zanotto Eberhardt, Raul Angelo Balbinot, Silvana Sartori Balbinot, Jonathan Soldera. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. Gastroenterología y Hepatología (English Edition) 2022; 45(1): 25 doi: 10.1016/j.gastre.2021.02.009
|
32 |
En Xian Sarah Low, Yen-Po Wang, Ching-Liang Lu. Risks of Proton Pump Inhibitors in Patients with Cirrhosis: Please Peruse the Indications. Digestive Diseases and Sciences 2024; 69(1): 7 doi: 10.1007/s10620-023-08153-3
|
33 |
Ellen Stein, Josh Sloan, Irene Sonu, Priya Kathpalia, Daniela Jodorkovsky. GERD for the nongastroenterologist: successful evaluation, management, and lifestyle‐based symptom control. Annals of the New York Academy of Sciences 2020; 1482(1): 106 doi: 10.1111/nyas.14496
|
34 |
Kelly L. Hayward, Rianne A. Weersink. Improving Medication‐Related Outcomes in Chronic Liver Disease. Hepatology Communications 2020; 4(11): 1562 doi: 10.1002/hep4.1612
|
35 |
Giulio Quarta, Cameron Zenger, David M. Feldman. Case–control study: Proton pump inhibitor use is a major risk factor for hepatic encephalopathy after TIPS. GastroHep 2021; 3(3): 172 doi: 10.1002/ygh2.450
|
36 |
Igor G. Bakulin, Inna A. Oganezova, Maria I. Skalinskaya, Ekaterina V. Skazyvaeva. Liver cirrosis and complication risk management. Terapevticheskii arkhiv 2021; 93(8): 963 doi: 10.26442/00403660.2021.08.200917
|
37 |
Hongsheng Yu, Mingkai Li, Bilan Yang, Huiying Sun, Hao Jiang, Zixi Liang, Abdukyamu Smayi, Bin Wu, Yidong Yang. Proton pump inhibitor use is associated with increased liver steatosis. Biomedical Reports 2024; 21(2) doi: 10.3892/br.2024.1804
|